Direct supply line from our multi-ton solid-phase peptide synthesis center, featuring comprehensive analytical verification (HPLC, MS, and residual screening).
An authoritative analysis of Ala-Glu-Asp-Gly (AGAG), telomeric repeat binding, pineal bioregulation, and solid-phase synthetic optimization.
Epitalon (Epithalon) is a synthetic tetrapeptide with the primary structural formula L-alanyl-L-alpha-glutamyl-L-alpha-aspartyl-glycine (H-Ala-Glu-Asp-Gly-OH), registered under CAS No. 307297-39-8. Originating from the pioneer biogerontological investigations of the pineal gland peptide extract (Epithalamin), this precise four-amino-acid motif constitutes the minimal active pharmacophore capable of pineal-telomeric signaling.
During commercial peptide synthesis, controlling the racemization of aspartic acid and glutamic acid is critical. Industrial-scale manufacture relies on orthogonal protection systems (Fmoc-tBu protocol) paired with non-racemizing coupling additives such as Oxyma Pure and DIC to prevent enantiomeric inversion at the chiral centers.
The primary mechanistic interest in Epitalon centers on its capacity to upregulate telomerase reverse transcriptase (TERT) expression. By binding site-specifically to the promoter region of the TERT gene, Epitalon facilitates open chromatin architecture (euchromatinization), allowing endogenous ribonucleoprotein telomerase complexes to elongate TTAGGG hexanucleotide tandem repeats at eukaryotic chromosomal termini.
This molecular interaction bypasses the classical Hayflick limit in human somatic diploid fibroblasts, restoring cellular proliferative capacity without oncogenic transformation, making it a critical research focus in regenerative medicine and clinical age-extension biotechnology.
Epitalon exhibits distinct biomimetic activity within the epiphyseal-hypothalamic axis. It induces chromatin unraveling in aging pinealocytes, leading to restored transcription of serotonin N-acetyltransferase (AANAT) and acetylserotonin O-methyltransferase (ASMT).
This restorative biochemical cascades re-establishes circadian nocturnal melatonin production peaks, optimizes nocturnal cortisol nadirs, and mitigates age-associated oxidative stress through direct down-regulation of lipid peroxidation byproducts and systemic free-radical scavenging pathways.
Factory-direct commercial wholesale pricing brackets, packaging formats, net peptide content standards, and counter-ion options for institutional buyers.
| SKU / Catalog No. | Grade / Formulation | Guaranteed Purity | Counter-Ion Type | Batch Scale Bracket | Indicative Price (USD) | Delivery Format |
|---|---|---|---|---|---|---|
| TH-EPI-010R | Research Diagnostic Grade | ≥ 98.0% (RP-HPLC) | Trifluoroacetate (TFA) | 10 g – 50 g | $14.50 – $18.00 / g | Lyophilized Powder |
| TH-EPI-100P | Preclinical Animal Grade | ≥ 98.5% (RP-HPLC) | TFA / Acetate Mixed | 100 g – 500 g | $9.20 – $12.00 / g | Sterile Lyovials |
| TH-EPI-1KGB | Semi-Commercial Pilot API | ≥ 99.0% (RP-HPLC) | Acetate (Pharmaceutical) | 1 kg – 5 kg | $6,200 – $7,500 / kg | Vacuum Double-PE Mylar |
| TH-EPI-IND | cGMP Clinical Trial API | ≥ 99.5% (RP-HPLC) | Acetate (< 1% Free TFA) | ≥ 10 kg Contract | Custom Quote / CDMO | Tamper-Evident Pharma Drums |
| TH-EPI-LYO10 | Finished Research Units | ≥ 98.5% (RP-HPLC) | Acetate / Mannitol Lyo | 1,000 – 10,000 Vials (10mg) | $3.80 – $5.20 / vial | 2ml Type-1 Borosilicate |
Procurement teams must distinguish between gross lyophilized cake mass and Net Peptide Content. Due to hygroscopic hydration water and stoichiometric counter-ions (acetate or trifluoroacetate), typical lyophilized peptide powder contains between 75% and 88% active peptide content. Every Thinheal batch provides quantitative elemental nitrogen determination and amino acid analysis (AAA) to report exact NPC.
Standard solid-phase cleavage utilizes 95% TFA, yielding peptide molecules electrostatically bound to trifluoroacetate anions. For cell-culture assays, human skin models, or prospective clinical developments, residual TFA can induce cytotoxicity. Thinheal performs continuous ion-exchange chromatography, converting crude TFA salts to pharmaceutical-grade acetate salts with residual TFA guaranteed < 0.5% or < 0.1%.
Epitalon is structurally stable in lyophilized format when stored desiccated at -20°C. For international logistics, Thinheal utilizes validated temperature-controlled insulated shippers with dry ice or phase-change materials, ensuring that international transit conditions prevent deamidation of asparagine/aspartic acid residues or thermal peptide rearrangement.
Addressing supply vulnerabilities, scale barriers, and regulatory convergence across North America, the European Union, and Asia-Pacific markets.
The global longevity biotherapeutics market is projected to expand at an unprecedented CAGR. Epitalon represents a cornerstone reference compound within geroscience, cellular reprogramming, and biological age deceleration. Increasing demand has created structural shortages in high-purity, traceable bulk peptide batches across western analytical centers.
A major systemic risk for peptide buyers is fragmented synthesis by intermediary brokers lacking physical reactors. Batch inconsistency, unaccounted truncated sequences (β-aspartyl rearrangements), and incomplete counter-ion declarations undermine reproducibility. Direct sourcing from primary synthesis bases eliminates intermediate markups and analytical opacity.
Transitioning from milligram academic synthesis to commercial multi-ton capacities requires profound engineering adjustments. Thinheal deploys continuous microwave-assisted peptide synthesis, industrial fluid-bed reactors, and automated preparative HPLC columns (up to 300mm internal diameter), delivering batch uniformity exceeding 99.0% purity at reduced solvent footprints.
The proliferation of unverified research chemical sellers distributing degraded, mislabeled, or high-endotoxin peptide vials poses major safety and legal liabilities. Global pharmaceutical partners require complete auditable manufacturing batch records (MBRs), verifiable NMR spectra, and traceable source documentation.
Ensuring compliance with US FDA, EMA, NMPA, and international pharmacopeial mandates for peptide Active Pharmaceutical Ingredients.
Thinheal provides end-to-end Chemistry, Manufacturing, and Controls (CMC) documentation packages. For partners pursuing investigational new drug (IND) or generic drug authorizations, we provide ready Drug Master File (DMF Type II) filing support, detailing validated synthesis routes, starting material specifications, critical process parameters (CPPs), and validation of impurity purge capabilities.
Every commercial lot of Epitalon is released against an uncompromising specification matrix:
To eliminate timezone latency and regulatory friction, Thinheal operates dedicated trade desks with native specialists:
Examining translational pathways from advanced biological research to therapeutic formulation and high-performance cosmeceuticals.
Epitalon serves as an active lead candidate in preclinical trials assessing telomere attrition mitigation. In animal models, continuous or cyclical administration of Epitalon demonstrated an extension in mean maximal lifespan, suppression of spontaneous tumor development, and restoration of immunological competence via thymus revitalization. Commercial clients formulate Epitalon into sterile injectable reconstitutions targeting degenerative chronic conditions.
Extensive neurochemical investigations highlight Epitalon's neuroprotective properties within retinal and cerebral tissues. In models of hereditary retinal degeneration (retinitis pigmentosa), Epitalon stimulates functional preservation of retinal bioelectrical activity and structural rod/cone integrity. Furthermore, through neuroendocrine modulation, it shields cortical neurons against excitotoxic beta-amyloid damage and ischemic reperfusion insults.
Due to its low molecular weight (390.35 Da), Epitalon possesses favorable transdermal flux compared to larger polypeptides. Skincare formulators incorporate palmitoylated or liposomal Epitalon formulations into premium anti-aging topicals. Cellular assays demonstrate that cutaneous fibroblast exposure to Epitalon boosts pro-collagen Type I and Type III synthesis, enhances extracellular matrix elastogenesis, and restores cellular resilience against environmental UV radiation.
Pioneering greener synthesis paradigms, AI-guided reaction kinetics, and advanced non-parenteral delivery systems.
Deployment of microfluidic packed-bed reactors replacing traditional stirred-tank vessels, cutting coupling cycle times from 45 minutes to under 3 minutes per residue while slashing DMF and NMP solvent consumption by 65%.
Integration of engineered peptide ligases for aqueous-phase assembly of Epitalon fragments. CEPS eliminates toxic protective group cleavage reagents and enables 100% green manufacturing compliance under international ESG directives.
Online Raman and near-infrared (NIR) spectroscopic monitoring coupled with neural-network feedback loops to optimize deprotection completeness and resin loading in real-time, ensuring zero-defect batch reproducibility at multi-ton scale.
Commercialization of proprietary lipid-core nanoparticle and cyclodextrin-inclusion formulations engineered to protect the AGAG tetrapeptide backbone against gastrointestinal peptidases, enabling effective oral solid dosage delivery.
Critical operational, regulatory, and quality insights addressing common pre-qualification inquiries from pharmaceutical and institutional buyers.
In its lyophilized powder state, Epitalon is highly stable. When maintained in desiccated, airtight containers protected from light at -20°C, stability data confirms less than 0.5% degradation over a validated 36-month period. For short-term transit (up to 30 days), ambient room temperature stability is fully supported by accelerated stress testing data without loss of HPLC purity.
Yes. In addition to bulk active pharmaceutical ingredient (API) powder in multi-kilogram containers, Thinheal operates sterile Class A lyophilization suites capable of filling, stoppering, and crimping custom 2ml, 5ml, and 10ml borosilicate glass vials with bulking agents (e.g., mannitol, glycine) at precise dosages (5mg, 10mg, 20mg, or 50mg per vial) under contract manufacturing agreements.
A standard HPLC chromatogram reports only the UV-absorbing area under the main peak relative to related substances. It fails to quantify non-UV-absorbing impurities, residual synthesis solvents (such as DMF, piperidine, acetonitrile), counter-ion ratios, moisture content, or bacterial endotoxins. A complete qualification review requires mass spectrometry (ESI-MS), Karl Fischer water titration, amino acid ratio confirmation, and LAL endotoxin testing.
Standard inventory for research-grade and pilot-scale quantities (up to 1 kg) is typically available for immediate dispatch within 48 to 72 hours. For custom commercial multi-kilogram campaigns requiring dedicated acetate exchange, specialized analytical validation, or cGMP batch documentation, production and release timelines range between 3 to 5 weeks from synthesis initiation to QA sign-off.
The presence of adjacent Asp and Gly residues in the sequence (H-Ala-Glu-Asp-Gly-OH) makes Epitalon structurally susceptible to aspartimide formation and subsequent β-aspartyl shift rearrangement under acidic or basic conditions. Our proprietary synthetic strategy utilizes bulky β-ester protecting groups (such as OtBu or OMpe) and low-temperature cleavage protocols to prevent succinimide cyclization, guaranteeing β-isomer impurities remain below 0.1%.
Discover our complementary catalog of tissue-regenerative, metabolic, and neuroprotective peptide APIs available for immediate global distribution.
Thin
